| Typicality: | 0.525 |
| Saliency: | 0.643 |
| in healthy volunteers | 8 | other |
| in patients with advanced solid tumors | 8 | other |
| along with its superiority over placebo | 7 | other |
| trial → evaluate → tolerability | 75 |
| trial → assess → tolerability | 55 |
| trial → determine → tolerability | 10 |
| trial → examine → tolerability | 8 |
| trial → investigate → tolerability | 8 |
| trial → compare → tolerability | 5 |
| trial → include → tolerability | 4 |
| negative | neutral | positive |
| 0.038 | 0.834 | 0.128 |
| Raw frequency | 165 |
| Normalized frequency | 0.643 |
| Modifier score | 0.500 |
| Perplexity | 479.649 |